Startseite Critical role of laboratory medicine in the global response to the COVID-19 pandemic
Artikel Öffentlich zugänglich

Critical role of laboratory medicine in the global response to the COVID-19 pandemic

  • Khosrow Adeli EMAIL logo
Veröffentlicht/Copyright: 2. Juni 2020
Veröffentlichen auch Sie bei De Gruyter Brill

The global coronavirus disease 2019 (COVID-19) has presented major challenges for clinical laboratories, from initial diagnosis to patient monitoring and treatment. As I write this editorial, many laboratory specialists, technologists, and trainees are selflessly and tirelessly standing on the front lines of the battle against COVID-19. This is happening at hospital laboratories and at private clinical laboratories around the globe. What is becoming very clear during this crisis is that clinical laboratory operations are critical in the global fight against this unprecedented pandemic through rapid diagnosis of viral infection, serological monitoring of the affected populations, and biochemical monitoring of hospitalized patients with more severe COVID-19-induced complications. Laboratory medicine is a key driver of healthcare delivery through provision of objective data to clinicians and other healthcare workers to guide appropriate clinical decision-making. Indeed, laboratory medicine is integral to prevention, diagnosis, treatment, and management of clinical disease including such infectious disease outbreaks. It supplies health care professionals with evidence-based data necessary to provide safe, effective, and high-quality care to patients.

Unfortunately, this essential role of laboratory medicine has not been widely recognized within healthcare organizations or the public, leading to poor visibility both within the field of clinical medicine and externally with the public at large. The current worldwide pandemic has clearly started to change the public’s and governmental view of the critical role that clinical laboratories play in public health and safety. It is now abundantly clear that without laboratory medicine appropriate public health measures and evidence-based care of hospitalized patients are simply not conceivable. In response to the current pandemic, the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) has established a global taskforce on COVID-19 (https://www.ifcc.org/executive-board-and-council/eb-task-forces/ifcc-task-force-on-covid-19/) as well as an online resource called the IFCC Information Guide on COVID-19 (https://www.ifcc.org/ifcc-news/2020-03-26-ifcc-information-guide-on-covid-19/). The taskforce and the online resource are helping to provide the latest evidence and up-to-date information on population screening, diagnosis, biosafety guidelines for clinical laboratories, and biochemical monitoring of hospitalized patients with COVID-19.

This first special issue of Clinical Chemistry and Laboratory Medicine (CCLM) on COVID-19 brings together a number of important reports and reviews, presenting the latest evidence on the laboratory management of this infection and the associated clinical complications. It includes a number of reviews, opinion pieces, and original articles on the pathogenesis of COVID-19 infection, as well as its laboratory diagnosis, surveillance, and monitoring of severely affected/hospitalized patients. The issue begins with comprehensive reviews on laboratory abnormalities associated with severity and mortality of COVID-19 as well as disease progression and intravascular coagulation. Two key articles are also included from the IFCC Taskforce, one on Biosafety Measures for Preventing Infection from COVID-19 in Clinical Laboratories: IFCC Taskforce Recommendations, and the second on Molecular, Serological, and Biochemical Diagnosis and Monitoring of COVID-19. These articles not only review the current evidence but also provide practical recommendations on both laboratory biosafety as well as diagnostic/serological/biochemical markers used in infection control and monitoring. In addition, a number of thoughtful opinion articles are included that discuss the critical role of laboratory medicine in the current pandemic, potential preanalytical and analytical concerns with diagnostic/serological testing, and lessons learned from the initial COVID-19 outbreak in Wuhan, China. Importantly, a series of original studies are published that provide very useful information on the performance of serological assays, specimens used in the collection and diagnosis of COVID-19, application of routine blood tests as potential diagnostic tools, lab-based predictive markers of COVID-19-associated death, hematological and coagulation abnormalities observed, as well as urine biochemical parameters that may predict disease severity.

This timely special issue of CCLM is a must read for all clinical laboratorians, clinicians, trainees, and other healthcare workers. It is an excellent collection of high-quality reviews and original papers that together provide a wide-ranging coverage of the role that clinical laboratories play in the fight against this unparalleled and unfortunate pandemic. I recognize this is a time of immense turmoil and disruption in our lives. No one knows how long this crisis will last but one thing is certain: clinical laboratories have visibly demonstrated their vital role and value in the public health surveillance and patient care and management, and are in the front line of the global response to COVID-19. On behalf of the IFCC organization, I would like to congratulate CCLM and its editors for putting together such a valuable and timely special issue which will undoubtedly become a treasured resource for laboratory medicine specialists and other healthcare workers around the world. On behalf of the Editorial Board of CCLM, I wish to thank all the authors for their comprehensive contributions on COVID-19 and hope that the readership of the journal will find interest in their content.

Published Online: 2020-06-02
Published in Print: 2020-06-25

©2020 Walter de Gruyter GmbH, Berlin/Boston

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. Critical role of laboratory medicine in the global response to the COVID-19 pandemic
  4. Reviews
  5. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis
  6. COVID-19: progression of disease and intravascular coagulation – present status and future perspectives
  7. IFCC Recommendations
  8. Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC taskforce evaluation of the latest evidence
  9. Biosafety measures for preventing infection from COVID-19 in clinical laboratories: IFCC Taskforce Recommendations
  10. Opinion Papers
  11. The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks
  12. Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19)
  13. Laboratory diagnostics within a modular hospital at the time of Coronavirus disease 2019 (COVID-19) in Wuhan
  14. Original Articles
  15. Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics
  16. Comparison of throat swabs and sputum specimens for viral nucleic acid detection in 52 cases of novel coronavirus (SARS-Cov-2)-infected pneumonia (COVID-19)
  17. Routine blood tests as a potential diagnostic tool for COVID-19
  18. Laboratory predictors of death from coronavirus disease 2019 (COVID-19) in the area of Valcamonica, Italy
  19. The hemocyte counts as a potential biomarker for predicting disease progression in COVID-19: a retrospective study
  20. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection
  21. The value of urine biochemical parameters in the prediction of the severity of coronavirus disease 2019
  22. Letters to the Editor
  23. COVID-19 infections are also affected by human ACE1 D/I polymorphism
  24. No significant correlation between ACE Ins/Del genetic polymorphism and COVID-19 infection
  25. ACE Ins/Del genetic polymorphism and epidemiological findings in COVID-19
  26. Laboratory abnormalities in patients with COVID-2019 infection
  27. Laboratory abnormalities in children with novel coronavirus disease 2019
  28. Clinical laboratory and SARS-CoV-2 infection: where do we stand?
  29. Clinical chemistry tests for patients with COVID-19 – important caveats for interpretation
  30. Antibody tests for COVID-19: drawing attention to the importance of analytical specificity
  31. Erythrocyte sedimentation rate is associated with severe coronavirus disease 2019 (COVID-19): a pooled analysis
  32. One disease, different features: COVID-19 laboratory and radiological findings in three Italian patients
  33. Decreased “WBC*LYM” was observed in SARS-CoV-2-infected patients from a fever clinic in Wuhan
  34. Assessment of immune response to SARS-CoV-2 with fully automated MAGLUMI 2019-nCoV IgG and IgM chemiluminescence immunoassays
  35. Coinfection of SARS-CoV-2 and multiple respiratory pathogens in children
  36. The friendly use of chloroquine in the COVID-19 disease: a warning for the G6PD-deficient males and for the unaware carriers of pathogenic alterations of the G6PD gene
  37. Potential interference of hydroxychloroquine-glucuronide metabolite on therapeutic drug monitoring of hydroxychloroquine using a mass spectrometry detector
Heruntergeladen am 13.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/cclm-2020-0742/html
Button zum nach oben scrollen